Soft tissue sarcomas involving the infratemporal fossa: a single-center experience with a systematic review.
Abstract
Objective
Soft tissue sarcomas (STSs) involving the infratemporal fossa (ITF) are extremely rare, and the existing literature is limited to case reports. We aim to describe their clinical characteristics and to analyze the risk factors affecting overall survival (OS) and progression-free survival (PFS).
Methods
A total of 30 STSs involving ITF cases were included, comprising 5 patients treated at our institution and 25 cases reported in the literature. Clinical data were systematically collected, and prognostic risk factors were analyzed using Kaplan-Meier survival analyze.
Results
Among the 30 patients included, one patient was an infant whose sex was not specified. Among the remaining 29 patients, there were 12 females and 17 males. Among all 30 available cases, the mean age was 35.0 ± 18.5 years (range, 0.25-72 years). A total of 14 (46.7%) patients had bone invasion. Regarding histopathological margin status, 6 (20%) cases were classified as R0, 15 (50%) as R1, and 9 (30%) as R2. After a mean follow-up of 31.3 ± 38.9 months, local recurrence occurred in 12 (42.9%) cases, postoperative lymph node metastasis occurred in 1 (3.8%) case, distant metastasis occurred in 4 (14.3%) cases, and 6 (21.4%) patients died. Kaplan-Meier survival curves were used to illustrate OS stratified by R0+R1 VS R2 (Chi Square = 3.949, p = 0.0469) and no bone invasion VS bone invasion (Chi Square = 7.458, p = 0.0063). Kaplan-Meier survival curves were used to illustrate PFS stratified by R0+R1 VS R2 (Chi Square = 7.672, p = 0.0056) and no bone invasion VS bone invasion (Chi Square = 5.588, p = 0.0181).
Conclusion
Bone invasion by the tumor was associated with poorer PFS and OS. Maximal surgical resection of the tumor, is the optimal treatment strategy. Whether to administer radiotherapy or chemotherapy postoperatively is determined by the specific pathological subtype. Further studies with larger cohorts are needed to validate our findings.